Protein kinase A activation by β‑Lapachone is associated with apoptotic cell death in NQO1‑overexpressing breast cancer cells

Zada,Sahib; Hwang,Jin  Seok; Ahmed,Mahmoud; Lai,Trang  Huyen; Pham,Trang  Minh; Kim,Dong‑Hee; Kim,Deok  Ryong

doi:10.3892/or.2019.7243

Protein kinase A activation by β‑Lapachone is associated with apoptotic cell death in NQO1‑overexpressing breast cancer cells

Authors:
- Sahib Zada
- Jin Seok Hwang
- Mahmoud Ahmed
- Trang Huyen Lai
- Trang Minh Pham
- Dong‑Hee Kim
- Deok Ryong Kim
View Affiliations

Affiliations: Department of Biochemistry and Convergence Medical Sciences, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, South Gyeongsang 527‑27, Republic of Korea, Orthopaedic Surgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, South Gyeongsang 527‑27, Republic of Korea
Published online on: July 19, 2019 https://doi.org/10.3892/or.2019.7243
Pages: 1621-1630

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

One million females are diagnosed worldwide every year with breast cancer, and the mortality rate of these patients remains high. Several treatments, including surgery, are available for breast cancer. β‑Lapachone (β‑Lap), a natural quinone compound, has been developed for cancer treatment due to its strong cytotoxic effect through its action on NAD(P)H:quinone oxidoreductase 1 (NQO1)‑dependent activity. However, the mechanism in regards to how β‑Lap induces cytotoxicity in breast cancer cells is still elusive. In the present study, we showed that β‑Lap induced apoptotic cell death via activation of protein kinase A (PKA) in NQO1‑overexpressing MDA‑MB‑231 human breast cancer cells. This PKA‑dependent cell death was observed solely in NQO1‑overexpressing 231 cells via the high production of reactive oxygen species (ROS). Cell survival of antioxidant [N‑acetylcysteine (NAC)]‑treated NQO1‑overexpressing 231 cells was significantly recovered, and NQO1‑negative 231 cells did not respond to β‑Lap. Antiapoptotic proteins such as Bcl2 and Bcl‑xL were decreased, while proapoptotic proteins, including cytochrome c, activation of caspase‑3, and cleavage of PARP were increased after β‑Lap treatment of NQO1‑overexpressing 231 cells. Furthermore, PKA activators, forskolin or dibutyryl‑cAMP, an analog of cAMP, aggravated the β‑Lap‑induced apoptotic cell death by decreasing antiapoptotic proteins and further activating proapoptotic proteins in NQO1‑positive 231 cells. Treatment with a PKA inhibiter, H89, significantly increased cell viability even in NQO1‑overexpressing cells treated with β‑Lap. These data showed that β‑Lap activated PKA via ROS accumulation, subsequently leading to apoptotic cell death in NQO1‑positive breast cancer cells.

View Figures

View References

1	Semenza GL: Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med. 18:534–543. 2012. View Article : Google Scholar : PubMed/NCBI
2	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lambert AW, Pattabiraman DR and Weinberg RA: Emerging biological principles of metastasis. Cell. 168:670–691. 2017. View Article : Google Scholar : PubMed/NCBI
4	Lerebours F and Lidereau R: Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 44:121–141. 2002. View Article : Google Scholar : PubMed/NCBI
5	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
6	Li CI, Beaber EF, Tang MC, Porter PL, Daling JR and Malone KE: Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. Breast Cancer Res Treat. 137:579–587. 2013. View Article : Google Scholar : PubMed/NCBI
7	Coughlin SS and Ekwueme DU: Breast cancer as a global health concern. Cancer Epidemiol. 33:315–318. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tangjitgamol S, Anderson BO, See HT, Lertbutsayanukul C, Sirisabya N, Manchana T, Ilancheran A, Lee KM, Lim SE, Chia YN, et al: Management of endometrial cancer in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 10:1119–1127. 2009. View Article : Google Scholar : PubMed/NCBI
9	Mark HF, Aswad B, Bassily N, Taylor W, Brown S, Sun CL, Samy M, Zolnierz K, Wong E, Bland KI and Hsu PH: HER-2/neu gene amplification in stages I–IV breast cancer detected by fluorescent in situ hybridization. Genet Med. 1:98–103. 1999. View Article : Google Scholar : PubMed/NCBI
10	Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
11	Fulda S: Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med. 13:1221–1227. 2009. View Article : Google Scholar : PubMed/NCBI
12	Varfolomeev E and Vucic D: Inhibitor of apoptosis proteins: Fascinating biology leads to attractive tumor therapeutic targets. Future Oncol. 7:633–648. 2011. View Article : Google Scholar : PubMed/NCBI
13	Taskén K and Aandahl EM: Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 84:137–167. 2004. View Article : Google Scholar : PubMed/NCBI
14	Fimia GM and Sassone-Corsi P: Cyclic AMP signalling. J Cell Sci. 114:1971–1972. 2001.PubMed/NCBI
15	Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M and Lord JM: Serine/threonine protein kinases and apoptosis. Exp Cell Res. 256:34–41. 2000. View Article : Google Scholar : PubMed/NCBI
16	Lerner A, Kim DH and Lee R: The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma. 37:39–51. 2000. View Article : Google Scholar : PubMed/NCBI
17	Insel PA, Bourne HR, Coffino P and Tomkins GM: Cyclic AMP-dependent protein kinase: Pivotal role in regulation of enzyme induction and growth. Science. 190:896–898. 1975. View Article : Google Scholar : PubMed/NCBI
18	Hedrick ED, Agarwal E, Leiphrakpam PD, Haferbier KL, Brattain MG and Chowdhury S: Differential PKA activation and AKAP association determines cell fate in cancer cells. J Mol Signal. 8:102013. View Article : Google Scholar : PubMed/NCBI
19	Almeida MQ and Stratakis CA: How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol Cell Endocrinol. 336:162–168. 2011. View Article : Google Scholar : PubMed/NCBI
20	Chowdhury S, Howell GM, Rajput A, Teggart CA, Brattain LE, Weber HR, Chowdhury A and Brattain MG: Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One. 6:e193352011. View Article : Google Scholar : PubMed/NCBI
21	Zambon AC, Zhang L, Minovitsky S, Kanter JR, Prabhakar S, Salomonis N, Vranizan K, Dubchak I, Conklin BR and Insel PA: Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA. 102:8561–8566. 2005. View Article : Google Scholar : PubMed/NCBI
22	Zhang L, Zambon AC, Vranizan K, Pothula K, Conklin BR and Insel PA: Gene expression signatures of cAMP/Protein Kinase A (PKA)-promoted, Mitochondrial-dependent Apoptosis: Comparative analysis of wild-type and camp-deathless s49 lymphoma cells. J Biol Chem. 283:4304–4313. 2008. View Article : Google Scholar : PubMed/NCBI
23	Coffino P, Bourne HR and Tomkins GM: Mechanism of lymphoma cell death induced by cyclic AMP. Am J Pathol. 81:199–204. 1975.PubMed/NCBI
24	Yan L, Herrmann V, Hofer JK and Insel PA: beta-Adrenergic receptor/cAMP-mediated signaling and apoptosis of S49 lymphoma cells. Am J Physiol Cell Physio. 279:C1665–C1674. 2000. View Article : Google Scholar
25	Zhang L and Insel PA: The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A-and glucocorticoid-promoted apoptosis of lymphoid cells. J Biol Chem. 279:20858–20865. 2004. View Article : Google Scholar : PubMed/NCBI
26	Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, Chiosi E, et al: Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther. 8:1183–1190. 2009. View Article : Google Scholar : PubMed/NCBI
27	Ugland H, Boquest AC, Naderi S, Collas P and Blomhoff HK: cAMP-mediated induction of cyclin E sensitizes growth-arrested adipose stem cells to DNA damage-induced apoptosis. Mol Biol Cell. 19:5082–5092. 2008. View Article : Google Scholar : PubMed/NCBI
28	Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA and Gao J: Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 70:3896–3904. 2010. View Article : Google Scholar : PubMed/NCBI
29	Li CJ, Li YZ, Pinto AV and Pardee AB: Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA. 96:13369–13374. 1999. View Article : Google Scholar : PubMed/NCBI
30	Dong Y, Chin SF, Blanco E, Bey EA, Kabbani W, Xie XJ, Bornmann WG, Boothman DA and Gao J: Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin cancer Res. 15:131–139. 2009. View Article : Google Scholar : PubMed/NCBI
31	Pardee AB, Li YZ and Li CJ: Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2:2002.227–242. View Article : Google Scholar : PubMed/NCBI
32	Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, Misico RI, Arzac GM, Burton G, Bornmann WG, et al: Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:Quinone oxidoreductase 1 levels. Clin Cancer Res. 11:3055–3064. 2005. View Article : Google Scholar : PubMed/NCBI
33	Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009. View Article : Google Scholar : PubMed/NCBI
34	Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D and Boothman DA: NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem. 275:5416–5424. 2000. View Article : Google Scholar : PubMed/NCBI
35	Siegel D, Yan C and Ross D: NAD(P)H:Quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 83:1033–1040. 2012. View Article : Google Scholar : PubMed/NCBI
36	Park EJ, Choi KS and Kwon TK: β-Lapachone-induced reactive oxygen species (ROS) generation mediates autophagic cell death in glioma U87 MG cells. Chem Biol Interact. 189:37–44. 2011. View Article : Google Scholar : PubMed/NCBI
37	Choi EK, Terai K, Ji IM, Kook YH, Park KH, Oh ET, Griffin RJ, Lim BU, Kim JS, Lee DS, et al: Upregulation of NAD(P)H:Quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia. 9:634–642. 2007. View Article : Google Scholar : PubMed/NCBI
38	Garate M, Wani AA and Li G: The NAD(P)H:Quinone oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med. 48:1601–1609. 2010. View Article : Google Scholar : PubMed/NCBI
39	Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S and Chen L: Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res. 33:142014. View Article : Google Scholar : PubMed/NCBI
40	Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW and Cullen JJ: Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog. 43:215–224. 2005. View Article : Google Scholar : PubMed/NCBI
41	Lyn-Cook BD, Yan-Sanders Y, Moore S, Taylor S, Word B and Hammons GJ: Increased levels of NAD(P)H:Quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. Cell Biol Toxicol. 22:73–80. 2006. View Article : Google Scholar : PubMed/NCBI
42	Li JZ, Ke Y, Misra HP, Trush MA, Li YR, Zhu H and Jia Z: Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent. Toxicol Appl Pharmacol. 281:285–293. 2014. View Article : Google Scholar : PubMed/NCBI
43	Cao L, Li LS, Spruell C, Xiao L, Chakraberti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, et al: Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxid Redox Signal. 21:237–250. 2014. View Article : Google Scholar : PubMed/NCBI
44	Liu Y, Yang F, Li S, Dai J and Deng H: Glutaredoxin deletion shortens chronological life span in saccharomyces cerevisiae via ROS-Mediated Ras/PKA activation. J Proteome Res. 17:2318–2327. 2018. View Article : Google Scholar : PubMed/NCBI
45	Li Z, Ji G and Neugebauer V: Mitochondrial reactive oxygen species are activated by mGluR5 through IP3 and activate ERK and PKA to increase excitability of amygdala neurons and pain behavior. J Neurosci. 31:1114–1127. 2011. View Article : Google Scholar : PubMed/NCBI
46	Bovo E, Lipsius SL and Zima AV: Reactive oxygen species contribute to the development of arrhythmogenic Ca²⁺ waves during β-adrenergic receptor stimulation in rabbit cardiomyocytes. J Physiol. 590:3291–3304. 2012. View Article : Google Scholar : PubMed/NCBI